# Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

> **NCT04676789** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** Pegaspargase
- **DRUG:** Anti-PD-1 monoclonal antibody
- **RADIATION:** Definitive intensity-modulated radiotherapy (IMRT)

## Key facts

- **NCT ID:** NCT04676789
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676789, "Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04676789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*